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Abstract
AIM: To clarify the association of interleukin-28B 
(IL28B ) single nucleotide polymorphisms (SNPs) with 
hepatitis C virus (HCV) viremia changes for assessment 
of interferon (IFN) response. 
METHODS: A cohort of 118 Caucasian treatment-naïve 
HCV-G1 infected patients, treated with pegylated-IFN 
alpha 2a or 2b associated with ribavirin (53 respond-
ers, 65 non-responders) during the period 2010-2012, 
were genotyped for IL28B  SNPs rs12979860 C>T and 
rs8099917 T>G. Genotyping was performed by real-
time allelic discrimination assay. Serum HCV RNA levels 
were assayed at 2, 4, 12, 24 and 48 wk during therapy. 
RETROSPECTIVE STUDY
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Correlation between IL28B  genotypes and serum HCV 
RNA kinetics was investigated. Multivariable logistic re-
gression analysis was performed to identify predictors 
of null-response.
RESULTS: Twenty-six out of 118 patients (22%) had 
no HCV RNA decline ≥ 1 log IU/mL at therapy week 
4 (null-responders). IL28B  genotype was rs8099917 
(G*)/rs1297860(**) in 21/26 (80%) of null-responder 
patients. Using multivariate analysis, it was shown 
that the presence of the rs8099917 G allele was the 
best predictor of null-response (OR = 7.9, 95%CI: 
1.99-31.18). The presence of at least one favorable 
genotype showed a positive predictive value of above 
90% for HCV RNA reduction ≥ log at week 4. Analysis 
of the HCV RNA kinetics during 12 wk of therapy in 
patients with IL28B  rs12979860 CT heterozygosis (n 
= 73), according to their rs8099917 status, showed 
that the viremia reduction was significantly different in 
patients carrying the rs8099917 G allele compared to 
those with favorable homozygosis.
CONCLUSION: Our findings emphasize the association 
of the IL28B  rs8099917 G allele with HCV. Genotyp-
ing for both IL28B SNPs is useful in clinical practice for 
thorough patient risk stratification based on IFN re-
sponsiveness.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: This work provides more insights into the ad-
vantage of interleukin-28B rs12979860 and rs8099917 
genotyping for therapy management in hepatitis C 
virus-G1 infected patients. The relevance of this ap-
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Patients who fail PEG-IFN/RBV therapy (non-respond-
ers, NR) are distinguished as follows: partial-responder 
(par-R) if  HCV RNA declines > 2 log IU/mL early on 
treatment but is still positive at week 12; null-responder 
(null-R) when HCV RNA reduction is less than 1 log at 
week 4 on treatment, and relapser (Rel) when HCV RNA 
is undetectable at end of  therapy but becomes posi-
tive during follow-up period[17]. Data from randomized 
controlled trials for PIs in pre-treated HCV-G1 patients 
clearly show that the pattern of  response to dual therapy 
strongly affects the probability of  achieving SVR after 
triple therapy, with a progressive increase in SVR rates 
from NR (31%-37%) to par-R (52%-57%) and to Rel 
(75%-86%)[5,6,18]. 
Although scientific communities and governmental 
health care organizations recommend triple therapy in 
HCV-G1 patients[19-21], the use of  PIs in clinical practice 
needs optimization, especially in distinguishing subjects 
who can still benefit from PEG-IFN/RBV therapy or 
those who need triple therapy or should wait for new, 
more potent drugs. In a recent multicentric study, includ-
ing 1045 HCV-G1 treatment-naïve patients, it has been 
shown that a consistent subset of  this cohort, identified 
by features such as IL28B genotype, could benefit from 
conventional dual therapy leading to a reduction in ad-
verse effects and economic costs[22,23]. 
The aim of  this study was to retrospectively investi-
gate the association of  IL28B SNPs with viremia changes 
at week 4 in a cohort of  treatment-naïve HCV-G1 infect-
ed patients during combination therapy and to evaluate 
the advantage of  typing for both SNPs for the identifica-
tion of  IFN-sensitive patients.
MATERIALS AND METHODS
One-hundred and eighteen patients (M/F 62/56, median 
age 49 years, interquartile range 16) with HCV-G1 infec-
tion undergoing antiviral therapy at the Gastroenterology 
and Hepatology Division of  Molinette Hospital, Turin, 
Italy, during the period 2010-2012, were retrospectively 
included in this analysis. Inclusion criteria were: (1) diag-
nosis of  chronic hepatitis C (CHC) G1; (2) serum HCV 
RNA positive; (3) Caucasian ethnicity; (4) no co-infection 
with hepatitis B virus, hepatitis delta virus and human 
immunodeficiency virus; and (5) naïve to HCV treatment. 
Patients were treated with standard doses of  PEG-IFN-
α-2a or -2b associated with RBV. Ribavirin dosage was 
based on weight: patients less than 75 kg received 800 
mg and those more than 75 kg received 1000-1200 mg. 
Therapy duration was 48 wk or less according to specific 
guideline stopping rules or to patients withdrawing due 
to severe side effects[24,25]. The stage of  liver fibrosis was 
described according to the METAVIR score. Significant 
fibrosis was defined as F3-F4. The AST-to-platelet ratio 
index (APRI) was calculated according to the formula 
proposed by Wai et al[26]. The research was approved by 
the institutional ethics committee and was performed ac-
cording to the 1979 Declaration of  Helsinki. All patients 
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proach is cost-effective at the time of decisions regard-
ing triple therapy. We observed that in rs12979860 het-
erozygous patients, carriage of the rs8099917 G allele 
correlated with lack of viremia decrease early during 
treatment, when it is critical to assess for interferon 
sensitivity.
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INTRODUCTION
For years, the standard of  care for hepatitis C virus 
genotype 1 (HCV-G1) infected patients consisted of  48 
wk of  combination therapy with pegylated-interferon α 
and ribavirin (PEG-IFN/RBV)[1]. This treatment regi-
men underwent a major change after the introduction 
of  direct antiviral agents (DAAs). DAAs directly inhibit 
specific steps in the HCV life cycle, for example, the two 
currently approved molecules, boceprevir and telapre-
vir, target NS3/4A serine protease (protease inhibitors, 
PIs)[2]. Triple therapy with PIs improves on-treatment ki-
netics and increases sustained virological response (SVR) 
rate with decreased duration of  therapy in both naïve and 
treatment-experienced HCV-G1 patients[3-6], but raises 
concerns regarding the generation of  resistant viral vari-
ants and significant side effects[7]. Furthermore, PIs are 
expensive and are not yet available in many countries[8]. 
With PEG-IFN/RBV therapy, pre-treatment patient 
features, such as viral genotype 1, older age, high base-
line viral load and the degree of  fibrosis, markedly affect 
the likelihood of  attaining a SVR and assist physicians 
in patient management[9]. A major breakthrough in the 
study of  baseline predictors of  dual therapy response has 
been the finding of  two single nucleotide polymorphisms 
(SNPs) rs12979860 and rs8099917, located near the in-
terleukin-28B (IL28B) gene encoding for IFN-λ-3, which 
display a strong association with SVR, mainly in HCV-G1 
infected patients[10-14]. Subjects with favorable IL28B gen-
otypes (such as CC for rs12979860 or TT for rs8099917) 
have a twofold improvement in SVR rates compared to 
patients carrying the risk allele for both SNPs. These 
genetic variants also affect viral kinetics on-therapy and 
during spontaneous viral clearance[15,16]. On-therapy vi-
remia changes are even more informative: achievement 
of  rapid viral response (RVR), defined as undetectable 
serum HCV RNA at treatment week 4, is considered the 
strongest predictor of  SVR, and the lack of  early viral 
response, defined as undetectable serum HCV RNA at 
week 12, has been correlated with treatment failure[15]. 
signed an informed consent for genetic testing.
Serum HCV RNA levels were assayed at 2, 4, 12, 24 
and 48 wk during therapy, using real-time polymerase 
chain reaction (PCR) assay with a limit of  detection of  
15 IU/mL (CAP/CTM HCV 2.0, Roche Molecular Diag-
nostics, Pleasanton, CA). Patients were monitored for at 
least 6 months after the end of  treatment in order to as-
sess therapy outcome. Genomic DNA was isolated from 
350 μL of  blood sample using the EZ1 DNA Blood 
kit (Qiagen GmbH, Hilden, Germany). Genotyping for 
IL28B SNP rs12979860 and rs8099917 was performed 
by real-time allelic discrimination assay (TaqMan SNP 
Genotyping Assay, Applied Biosystems, Foster City, CA) 
using TaqMan SNP Genotyping Master Mix (Applied 
Biosystems) on a CFX96 Real-time PCR instrument (Bio-
Rad Laboratories, Hercules, CA).
Statistical analysis
Continuous variables are summarized as median ± in-
terquartile range, and categorical variables as frequency 
and percentage. Comparisons between groups were per-
formed using a Mann-Whitney U-test for non-normal 
continuous variables. For categorical data, the Fisher 
exact test was used. P < 0.05 (two-sided) was considered 
statistically significant. Stepwise logistic regression analy-
sis was performed to identify predictors of  null-R. For 
the regression model, the IL28B SNPs were evaluated ac-
cording to the presence of  the risk allele vs favorable ho-
mozygosis. All calculations were performed using SPSS 
software version 20.0 (IBM SPSS Statistics for Windows, 
Chicago, IL).
RESULTS
A total of  118 Caucasian HCV-G1 infected patients were 
included in the study. Demographics and clinical char-
acteristics of  the patient cohorts are reported in Table 
1. IL28B typing showed that 59 of  them (50%) carried 
genotype TG/GG at rs8099917 while 88 (75%) had 
genotype CT/TT at rs12979860.
Twenty-six patients out of  118 (22%) did not achieve 
an HCV RNA drop ≥ 1 log at week 4 (null-R) and 21/26 
(81%) carried the rs8099917 G allele. All of  them were 
NR to therapy at week 12. Univariate analysis revealed 
that baseline factors which were significantly associated 
with null-R were higher levels of  AST, ALT, gGT (P = 
0.032, 0.002, 0.001 respectively), lower platelet levels (P = 
0.019), higher APRI index (P = 0.033) and the carriage of  
the rs8099917 G allele (P < 0.001). After logistic regres-
sion analysis, rs8099917 G allele carriage was determined 
to be the best predictor of  null-R (OR = 7.9, 95%CI: 
1.99-31.18, Table 2).
The predictive value analysis of  single and combined 
IL28B SNPs for achieving HCV RNA decline ≥ 1 log 
after 4 wk of  treatment shows that the presence of  at 
least one favorable genotype yields a positive predictive 
value (PPV) above 90%, with the combination of  both 
SNPs showing a mild improvement (likelihood ratio = 
3.82), Table 3.
We analyzed HCV RNA kinetics during 12 wk of  
therapy in patients with IL28B rs12979860 CT heterozy-
gosis (n = 73), according to their rs8099917 status. The 
reduction in viral load during treatment was significantly 
different in patients carrying the rs8099917 G allele 
compared to those with favorable homozygosis (P < 
0.01). The decrease in serum HCV RNA levels at week 
2, 4 and 12 was 2.1, 3.5 and 6.2 log10 in patients with the 
rs8099917 TT compared to 0.9, 1.55 and 3.7 log10, respec-
tively, in those with the unfavorable TG/GG genotypes (P 
< 0.001), Figure 1. 
DISCUSSION
The major implication for recommending triple rather 
than dual therapy for HCV-G1 patients is that higher 
numbers of  patients may achieve a RVR and most likely 
respond to treatment. Considering the enthusiasm in the 
run to embrace new therapies, it should not be forgot-
ten that an appreciable number (about 20%) of  HCV-G1 
patients (mainly those experiencing RVR) are able to 
eliminate the virus with conventional dual therapies[22]. 
The treatment risk/benefit ratio is mainly bound to the 
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Table 1  Demographic and clinical features of 118 hepatitis 
C virus genotype 1 infected patients  n  (%)
Variables Patients
Age, yr   49 (16)
Male gender 52.5%
BMI, kg/m2 23.5 (3.6)
AST, IU/mL   82 (71)
ALT, IU/mL   55 (48)
gGT, IU/mL   46 (57)
Platelets, 109 L 182 (90)
APRI index   0.4 (0.6)
Basal HCV RNA, log IU/mL      6 (1.1)
Fibrosis (stiffness)  6.7 (19)
Fibrosis Metavir
   F0-F1-F2   20 (25)
   F3-F4   59 (75)
IL28B SNP rs8099917
   TT   59 (50)
   TG   56 (47)
   GG   3 (3)
IL28B SNP rs12979860
   CC   30 (25)
   CT   73 (62)
   TT   15 (13)
HCV RNA decline < 1 log10 IU/mL w4   26 (22)
   rs8099917_G*/rs12979860_**   21 (81)
   rs8099917_TT/rs12979860_T*     3 (11)
   rs8099917_TT/rs12979860_CC   2 (8)
Therapy outcome
   R   53 (55)
   NR   65 (45)
Data are reported as median (interquartile range) and frequencies (%). 
IL: Interleukin; BMI: Body mass index; ALT: Alanine aminotransferase; 
AST: Aspartate aminotransferase; gGT: Gamma-glutamyl transpeptidase; 
IL28B: Interleukin-28B; SNP: Single nucleotide polymorphism; w4: Treat-
ment week 4; R: Responder; NR: Non-responder.
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at rs12979860 than in those with non-CC. This suggests 
that innate immunity may still be important and confirms 
the importance of  IL28B genotyping in the context of  
new and future therapy regimens[30].
Our data show that IL28B rs8099917 G allele car-
riage is the most significant baseline feature associated 
with lack of  IFN sensitivity at week 4, in treatment-naïve 
HCV-G1 infected patients treated with PEG-IFN/RBV, 
independently of  rs12979860T allele carriage. Evalua-
tion of  the PPV for the HCV RNA decrease ≥ 1 log at 
treatment week 4 according to each single SNP shows 
no difference between them, with a mild likelihood ratio 
for the two SNPs together. Nevertheless, the combined 
IL28B genotype of  week-4 null-R was rs8099917_G*/
rs1297860_** in 21/26 (80%) patients. In our cohort, all 
null-R become NR at week 12 and may be considered as 
interferon insensitive. 
The IL28B locus (coding for IFN-λ3) is pivotal to the 
pathogenesis of  HCV chronic infection[9-13]. Two SNPs, 
rs8099917 T/G and rs12979860 C/T, located 8 and 3 
kb upstream of  the IL28B gene, respectively, showed the 
strongest association with SVR to dual therapy, especially 
in HCV-G1 infected patients. Both SNPs are in linkage 
disequilibrium but allele frequencies may be quite dif-
ferent among different ethnic groups. In addition, it has 
been reported that IL28B genetic variants affect HCV 
RNA decline early on therapy[15-17].
The mechanism by which the IL28B genetic vari-
ants influence the efficacy of  dual treatment remains 
unknown and the need to genotype for both SNPs in the 
clinical setting, prior to therapy, remains questionable. In 
the majority of  studies, only one SNP, either rs12979860 
or rs8099917, was assayed according to prevailing ethnic-
ity. In Japan, the favorable rs8099917_T allele has higher 
frequency in the general population compared to Cauca-
sians, thus explaining why there is higher spontaneous or 
therapy-induced clearance of  HCV infection, and why 
incidence and severity of  side effects, which are signifi-
cantly increased with triple therapy and occur mostly 
in the main candidates for treatment, i.e., patients with 
advanced fibrosis or cirrhosis[26]. In a multicentric French 
trial, including about 500 cirrhotic treatment-experienced 
patients treated with triple therapy (CUPIC cohort), 40% 
showed serious adverse events, with high rates of  discon-
tinuation, and there were 1.7% and 0.5% cases of  mortal-
ity in the groups treated with telaprevir and boceprevir, 
respectively[27]. Moreover, both PIs are metabolized 
through cytochromes P450 3A4 and 3A5. With regard 
to this, the risk of  drug-drug interactions is a concern in 
clinical practice[28,29]. 
In the era of  DAAs, IL28B testing offers the mini-
mal additional information that could influence the 
clinician’s decision[27]. Nevertheless, triple therapy is not 
recommended in all patients and the evaluation of  pre-
treatment factors such as the IL28B SNPs still holds 
significance to establish the therapeutic schedule. More-
over, in a recent review, Matsuura et al[30] reported that 
IL28B polymorphisms may affect viral kinetics even in 
the context of  IFN-free regimens. In a phase 2, random-
ized, open-label trial of  faldaprevir (NS3/4A protease 
inhibitor) and deleobuvir (NS5B polymerase inhibitor), 
the SVR rates tended to be higher in patients with CC 
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Table 2  Univariate and multivariate analysis of baseline factors associated with hepatitis C virus RNA reduction < 1 log10 IU/mL at 
week 4 on treatment  n  (%)
Baseline factors Univariate Multivariate
HCV RNA drop <1 log10: w4 HCV RNA drop ≥ log10: w4 P  value OR 95%CI P  value
(n  = 26) (n  = 92)
Age, yr   49 (14)   49 (18) NS - - NS
Male gender   15 (26)   47 (74) NS - - NS
BMI, kg/m2 23 (2) 24 (4) NS - - -
AST, IU/mL   90 (46)   67 (74)    0.032 1.01 0.99-1.02 NS
ALT, IU/mL   73 (60)   49 (44)    0.002 0.97 0.95-0.99 0.018
gGT, IU/mL   68 (71)   39 (43)    0.001 0.99 0.98-0.99 0.009
Platelets, 109 L 151 (93) 196 (83)    0.019 - - NS
APRI index   0.6 (1.2)   0.4 (0.6)    0.033 - - NS
Basal HCV RNA, log IU/mL   6.1 (0.8)      6 (1.1) NS - - -
Fibrosis F3/F4   11 (58)   48 (80) NS - - NS
IL28B rs8099917_TG/GG   21 (81)   38 (41) < 0.001 7.90   1.99-31.18 0.003
IL28B rs12979860_CT/TT   23 (88)   65 (71) NS - - NS
Data are reported as median (interquartile range) and frequencies (%). IL: Interleukin; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspar-
tate aminotransferase; gGT: Gamma-glutamyl transpeptidase; Null-R: Null-responders; NS: Not significant.
Table 3  Sensitivity, specificity, positive and negative predic-
tive value of single and combined IL28B polymorphisms for 
achieving hepatitis C virus RNA drop ≥ 1 log at treatment 
week 4
IL28B polymorphisms Sn Sp PPV NPV LR
rs8099917_TT 59% 81% 91% 36% 3.05
rs12979860_CC 29% 88% 90% 26% 2.54
rs8099917_TT or rs12979860_CC 29% 92% 93% 27% 3.82
IL: Interleukin; Sn: Sensitivity; Sp: Specificity; PPV: Positive predictive 
value; NPV: Negative predictive value; LR: Likelihood ratio.
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genotyping for this SNP is informative enough. More-
over, in the European cohort of  910 G1 CHC patients 
analyzed by Suppiah et al[31], IL28B rs8099917 TG/GG 
variants were associated with lack of  treatment-induced 
clearance. Halfon et al[32] reported that analysis of  a single 
IL28B SNP was sufficient to predict treatment failure in 
patients with HCV. Furthermore, Lazarevic et al[33], com-
paring 3 Il28B SNPs, observed that the rs12979860 CC 
genotype was a better predictor of  therapy success in a 
cohort of  106 HCV patients. 
Our study confirms that IL28B alleles impact on vi-
ral kinetics during treatment in patients with HCV-G1 
infection. In order to investigate the usefulness of  typing 
for both SNPs, we analyzed HCV RNA kinetics dur-
ing 12 wk of  therapy in the sub-group of  patients with 
rs12979860 heterozygosis with respect to rs8099917 
genotypes. We observed a significant difference for HCV 
RNA decline in the absence of  rs8099917 G allele car-
riage. These observations highlight the association of  the 
IL28B rs8099917 G allele with the lack of  HCV RNA re-
duction > 1 log at treatment week 4 in HCV-G1 patients 
treated with PEG-IFN/RBV therapy. Thus, genotyping 
for both IL28B SNPs is advantageous in clinical practice 
for patient risk stratification at therapy week 4, a key 
time-point for assessment of  IFN responsiveness before 
the addition of  PIs. In patients with favorable IL28B gen-
otypes and RVR, clinicians could still afford to treat with 
combination therapy, with no addition of  first generation 
PIs and without losing therapy response. With the new 
and future antiviral regimens entering clinical practice (2nd 
class PIs and IFN-free regimens), IL28B genotyping may 
guide clinicians to offer personalized therapy to difficult-
to-treat patients, hopefully sparing side effects and costs. 
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cure rates (about 70% to 80%) than dual therapy with pegylated interferon 
(Peg-IFN) plus ribavirin (RBV) and may allow reduction in treatment duration. 
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morphisms, markedly affect the likelihood of attaining a sustained virological 
response (SVR) and assist physicians in patient management.
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tion at therapy week 4, a key time-point for assessment of interferon respon-
siveness before the addition of PIs. The results of this study provide a strong 
rationale for the use of IL28B single nucleotide polymorphism (SNPs) testing to 
personalize antiviral therapy.
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This work aims at emphasizing the role of IL28B polymorphism genotyping 
in HCV genotype-1 patients for whom triple therapy is not suited. In these 
patients, the evaluation of pre-treatment factors such as the IL28B SNPs still 
holds significance to establish the therapeutic schedule. 
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In patients with favorable IL28B genotypes and rapid viral response (RVR), 
clinicians could still afford to treat with combination therapy, with no addition of 
first generation PIs and without losing therapy response. The relevance of this 
approach is cost-effective at the time of triple therapy.
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IL28B is a cytokine that plays a role in immune defense against viruses, in-
cluding the induction of an “antiviral state”. Two SNPs, rs8099917 T/G and 
rs12979860 C/T, located 8 and 3 kb upstream of the IL28B gene, respectively, 
showed the strongest association with SVR to PEG-IFN/RBV therapy, espe-
cially in HCV-G1 infected patients.
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IFN responsiveness.
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